AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own DocuSign, you need to believe it can evolve from a mature e-signature vendor into an AI-first agreement platform that supports healthier recurring growth without sacrificing profitability. The latest quarter’s 8.4% revenue increase and guidance raise support that narrative, while analyst focus on Intelligent Agreement Management (IAM) puts near term execution on that platform at the center of the story. The biggest current risk is that IAM and related AI offerings fail to deliver the upsell and adoption levels embedded in expectations.
The EUR4.5 million expansion of DocuSign’s AI Centre of Excellence in Dublin looks most relevant here, because it directly addresses the company’s push to build out IAM and identity capabilities for larger European and global customers. If that investment helps deepen integrations and improve trust, security and compliance for regulated industries, it could reinforce the core catalyst of higher value agreement workflows, even as competition and commoditization fears in e-signature and AI enabled tools remain front of mind.
Yet while the AI and Europe story is appealing, investors should also be aware of the risk that IAM adoption among DocuSign’s 1.7 million customers...
Read the full narrative on DocuSign (it's free!)
DocuSign's narrative projects $3.8 billion revenue and $359.8 million earnings by 2028. This requires 7.3% yearly revenue growth and about a $78.8 million earnings increase from $281.0 million today.
Uncover how DocuSign's forecasts yield a $86.50 fair value, a 24% upside to its current price.
Six fair value estimates from the Simply Wall St Community cluster between US$77 and about US$118, showing how differently individual investors see DocuSign’s potential. Against that diversity of views, the key question remains whether DocuSign’s AI powered agreement management and European expansion can offset signs of a maturing core e-signature market and growing competitive pressure.
Explore 6 other fair value estimates on DocuSign - why the stock might be worth as much as 69% more than the current price!
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com